格隆汇11月3日丨威高股份(01066.HK)公布，截至2025年9月30日止3个月，公司录得未经审核的收入约 人民币32.6亿元，较去年同期增长约2.6%。其中，骨科、介入、血液管理等分部取得较快收入增长；而 药品包装和通用医疗器械分部，由于冲管注射器等产品的销售价格受政策影响持续承压，对集团整体销 售收入增长有所拖累。 相关事件 威高股份(01066.HK)第三单季度未经审核收入32.6亿元 同比增长约2.6% 威高股份(01066.HK)拟将威高 普瑞注入威高血净 交易完成后或并表 ...

山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 自願性公告 第三季度最新營運表現 通用醫療器械 低個位數下降 藥品包裝 低個位數上升 介入 超過10%上升 本公告乃由山東威高集團醫用高分子製品股份有限公司（「本公司」，連同其附 屬公司統稱「本集團」）董事會（「董事會」）自願發出，以提供本集團近期之營運 表現。 截至2025年9月30日止3個月，本公司錄得未經審核之收入約人民幣32.6億元， 較去年同期增長約2.6%。其中，骨科、介入、血液管理等分部取得較快收入增 長；而藥品包裝和通用醫療器械分部，由於沖管注射器等產品的銷售價格受 政策影響持續承壓，對集團整體銷售收入增長有所拖累。 * 僅供識別 1 以下為各經營分部的收入較去年同期 ...

Core Viewpoint - The company plans to issue shares to acquire 100% equity of Weigao Puri from Weigao Co., Weihai Shengxi, and Weihai Ruiming, which is expected to constitute a major asset restructuring for the listed company [2] Group 1: Transaction Details - The transaction will add new business lines in the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems [2] - Following the completion of the transaction, the company aims to integrate the target company's technological accumulation and product layout to expand its product line into the pharmaceutical packaging sector [2] Group 2: Strategic Benefits - The company plans to leverage its own hollow fiber filtration technology advantages alongside the target company's rich customer resources in the biopharmaceutical sector [2] - This collaboration is expected to enable mutual empowerment in product technology reserves and sales channels for biopharmaceutical filter business, focusing on the upstream market of biopharmaceuticals [2]

Core Viewpoint - Weigao Group (01066.HK) announced a conditional sale agreement for Weigao Purui, aiming to enhance its stake in Weigao Xuejing and expand its overall business footprint and profitability through synergies [1] Group 1: Transaction Details - Weigao Xuejing will acquire 100% of Weigao Purui's shares, with the transaction price set at RMB 31.29 per share for the consideration shares issued to Weigao Purui's shareholders [1] - The number of consideration shares to be issued will be calculated based on the final transaction price divided by the issuance price per share [1] - Following the completion of the transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Xuejing, which may then become a non-wholly-owned subsidiary of the company [1] Group 2: Ownership and Financial Implications - As of the announcement date, the company holds a 23.53% stake in Weigao Xuejing [1] - The transaction is expected to increase the company's ownership in Weigao Xuejing and integrate the financial accounts of Weigao Purui and Weigao Xuejing into the company's financial statements [1] - The board believes that the transaction will create synergies between Weigao Purui and Weigao Xuejing, further expanding the company's overall business landscape and enhancing profitability [1]

Core Viewpoint - Weigao Group (01066.HK) announced a conditional sale agreement for Weigao Purui, aiming to enhance its stake in Weigao Xuejing and expand its overall business footprint and profitability through synergies [1] Group 1: Transaction Details - Weigao Xuejing will acquire 100% of Weigao Purui's shares, with the transaction price set at RMB 31.29 per share for the consideration shares issued to Weigao Purui's shareholders [1] - The number of consideration shares to be issued will be calculated based on the final transaction price divided by the issuance price per share [1] - Following the completion of this transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Xuejing, while Weigao Xuejing may become a non-wholly-owned subsidiary of the company [1] Group 2: Ownership and Financial Implications - As of the announcement date, the company holds a 23.53% stake in Weigao Xuejing, which is expected to increase post-transaction [1] - The financial accounts of Weigao Purui and Weigao Xuejing may be consolidated into the company's financial statements, enhancing overall business scale [1] - The board believes that the transaction will create synergies between Weigao Purui and Weigao Xuejing, leading to an expansion of the group's business landscape and improved profitability [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 交易進展更新 本次交易 董事會謹此宣佈，於2025年10月31日（交易時段後），本公司、威海盛熙、威海 瑞明及威高血淨，簽訂了附生效條件的買賣協議，據此威高血淨將收購本公 司非全資附屬公司威高普瑞100%的股權；作為交易對價，威高血淨將向各 威高普瑞股東發行相應數量的對價股份。 出售事項 根據買賣協議，本公司及威海瑞明作為賣方將參考標的資產的評估值，按照 商定價格合共向威高血淨出售威高普瑞95.9784%的股權。最終對價有待標 的資產評估完成後，各方訂立補充協議確定。 * 僅供識別 1 收購事項 威高血淨將按照每股對價股份人民幣31.29元分別向各威高普瑞股東發行相 應數量的對價股份 ...

Core Insights - Weigao Group (01066) reported its subsidiary Weigao Orthopedics (688161.SH) third-quarter performance for 2024, achieving a revenue of 1.106 billion yuan, a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders was 207 million yuan, reflecting a year-on-year growth of 26.24%, with basic earnings per share at 0.52 yuan [1] - The announcement indicated that the overall execution of orthopedic bulk procurement remained stable, with domestic leading brands increasing their market share [1] Revenue and Profit Performance - The company recorded a revenue of 1.106 billion yuan for the first three quarters, marking a 2.12% increase compared to the previous year [1] - Net profit attributable to shareholders reached 207 million yuan, which is a 26.24% increase year-on-year [1] - Basic earnings per share stood at 0.52 yuan [1] Market and Operational Strategy - The orthopedic bulk procurement execution was reported to be stable during the reporting period [1] - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - This transformation aims to optimize and upgrade the marketing structure, enhance the professionalism and flexibility of the sales team, and significantly improve clinical service levels, leading to sustained growth in revenue and sales volume [1]

Core Insights - Weigao Co., Ltd. reported a revenue of 1.106 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders reached 207 million yuan, marking a year-on-year increase of 26.24% [1] - Basic earnings per share stood at 0.52 yuan [1] Revenue and Profit Performance - The company experienced stable execution of bulk procurement in the orthopedic sector during the reporting period [1] - The market share of leading domestic brands in the orthopedic field continued to rise [1] Strategic Initiatives - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - This transformation aims to optimize and upgrade the marketing structure, leading to increased specialization and flexibility within the sales team [1] - Enhanced professional service levels in clinical settings have contributed to sustained growth in revenue and sales volume across product lines [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 海外監管公佈 本公佈乃根據香港聯合交易所有限公司證券上市規則第13.10B條之披露規定 作出。根據中華人民共和國之相關規定，山東威高骨科材料有限公司於上海 證券交易所網站(http://www.sse.com.cn/home/search/?webswd=688161)刊發公 佈。 承董事會命 山東威高集團醫用高分子製品股份有限公司 董事長 龍經 二零二五年十月三十日 中國山東省威海市 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * 於本公佈刊發日期，董事會成員包括： 龍 經先生 （執行董事） 叢日楠先生 （執行董事） 盧均強先生 （執行董事） 王道明先生 （執行董事） 陳 林先生 （非執行董事） 湯正鵬先生 （非執行董事） 李國 ...

Core Viewpoint - Multiple companies, including China Feihe and Lianyi Rong Technology, conducted share buybacks on October 24, 2025, with China Feihe leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 5.885 million shares for a total of 23.6977 million yuan, representing 0.087% of its total share capital [2]. - Lianyi Rong Technology (09959) repurchased 2.4 million shares for 7.3782 million yuan, accounting for 3.516% of its total share capital [2]. - Beike-W (02423) repurchased 1.1784 million shares for 7 million yuan, which is 1.722% of its total share capital [2]. Group 2: Other Notable Buybacks - Yum China (09987) repurchased 17,800 shares for 6.2549 million yuan, representing 2.830% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 400,000 shares for 5.7447 million yuan, which is 0.545% of its total share capital [2]. - Kangsong Pharmaceutical (01681) repurchased 100,000 shares for 1.5180 million yuan, accounting for 8.582% of its total share capital [2].